MediWound (NASDAQ:MDWD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MediWound (NASDAQ:MDWD) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Several other research analysts have also commented on MDWD. TD Cowen reaffirmed a “buy” rating on shares of MediWound in a report on Thursday. Weiss Ratings lowered shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Oppenheimer reissued an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Finally, Alliance Global Partners restated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.00.

MediWound Stock Performance

Shares of MDWD stock opened at $13.93 on Friday. The stock has a market capitalization of $179.00 million, a price-to-earnings ratio of -7.74 and a beta of 0.14. MediWound has a one year low of $12.52 and a one year high of $20.03. The company’s 50-day simple moving average is $13.65 and its 200-day simple moving average is $15.03.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. As a group, research analysts forecast that MediWound will post -2.37 EPS for the current year.

Insider Activity at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MediWound stock. Silverberg Bernstein Capital Management LLC boosted its stake in MediWound Ltd. (NASDAQ:MDWD) by 8.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 200,005 shares of the biopharmaceutical company’s stock after buying an additional 16,081 shares during the period. MediWound accounts for 1.8% of Silverberg Bernstein Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Silverberg Bernstein Capital Management LLC owned about 1.56% of MediWound worth $3,222,000 as of its most recent filing with the Securities & Exchange Commission. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.